Piper Sandler on MiniMed Group (MMED): 'Nice Start as a Public Entity but Still Plenty to Prove'

June 4, 2026 8:01 AM

Piper Sandler analyst Matt O'Brien reiterated a Neutral rating and $16.00 price target on MiniMed Group (NASDAQ: MMED).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found